Alembic Pharmaceuticals, Inc. is the U.S. subsidiary of Alembic Pharmaceuticals Limited, an Indian pharmaceutical group. The Inc. entity is a Delaware corporation with its principal U.S. office at 750 Route 202, Bridgewater, New Jersey; court filings describe it as a wholly owned subsidiary of Alembic Global Holding SA, which in turn is wholly owned by Alembic Pharmaceuticals Limited. The parent is headquartered in Vadodara, Gujarat; its corporate history dates to 1907 (the listed entity was incorporated in 2010) and it trades on the NSE/BSE under APLLTD. It is public, with roughly 15,000–20,000 employees depending on source and consolidated revenue of about ₹6,672 crore in FY25 (~US$800M).
Operations. The group is a vertically integrated generics, branded-generics and API manufacturer. Its three divisions are international generics (oral solids, dermatology, ophthalmology, general and oncology injectables, supplied from five+ U.S. FDA-approved plants in India, plus the Aleor Dermaceuticals dermatology subsidiary), Indian branded formulations (gynaecology, anti-diabetic, ophthalmology, dermatology, anti-infectives, cough/cold and animal health, sold via a ~5,500-person field force), and active pharmaceutical ingredients/intermediates. Alembic reports 220+ cumulative U.S. ANDA approvals and 260+ filings; the U.S. front-end subsidiary markets generic solid oral, dermatology and ophthalmic products.
Litigation posture. Alembic is an operating company, not an assertion entity: it appears once in the tracked data, as a defendant (0 plaintiff-side suits). The suit is a standard Hatch-Waxman ANDA action in the U.S. District Court for the District of Delaware — a conventional pharmaceutical venue, not a plaintiff-friendly NPE district.
Notable case. Array BioPharma, Inc. v. Alembic Pharmaceuticals Limited et al., No. 1:22-cv-01277 (D. Del., filed 2022-09-28), concerned six patents covering binimetinib (Mektovi) formulations and combination use with encorafenib, triggered by Alembic's ANDA No. 217678 for 15 mg binimetinib tablets. Array is a Pfizer subsidiary. Alembic counterclaimed; Alembic Pharmaceuticals, Inc. was dismissed from the case by stipulation in November 2022. The action was dismissed in June 2025 under a settlement and license agreement barring U.S. marketing of the accused product. Alembic later received tentative FDA approval for binimetinib 45 mg as sole first applicant.